Trials / Conditions / Central Nervous System Neoplasms

Central Nervous System Neoplasms

26 registered clinical trials studyying Central Nervous System Neoplasms — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	B7-H3.CD28Z.CART in CNS Neoplasms NCT07390539	Robbie Majzner	Phase 1
Not Yet Recruiting	5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gli NCT05850377	Sociedad de Lucha Contra el Cáncer del Ecuador	—
Recruiting	Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors NCT05835687	St. Jude Children's Research Hospital	Phase 1
Terminated	RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant NCT04525014	EpicentRx, Inc.	Phase 1
Recruiting	Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer NCT05386108	Stemline Therapeutics, Inc.	Phase 1 / Phase 2
Unknown	Pediatric Prospective Personalized Immune and Target Identification Trial NCT04859543	Masaryk University	N/A
Unknown	Diagnostic Efficiency of Artificial Intelligence for Surgical Neuropathology NCT04671368	Jinsong Wu	N/A
Recruiting	Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082	Jazz Pharmaceuticals	Phase 1
Terminated	Mapping Draining Lymph Nodes in CNS Malignancies NCT04096716	Washington University School of Medicine	Phase 1
Completed	Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs NCT03750188	Bracco Diagnostics, Inc	—
Completed	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies fo NCT03434262	St. Jude Children's Research Hospital	Phase 1
Completed	Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma NCT03188354	Norwegian University of Science and Technology	N/A
Completed	A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain NCT03257631	Celgene	Phase 2
Completed	Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients NCT03147989	Bracco Diagnostics, Inc	—
Terminated	Biomarker Analysis of Central Nervous System Tumors NCT02692898	National Cancer Institute (NCI)	—
Completed	Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) NCT01931098	National Cancer Institute (NCI)	Phase 2
Completed	Retrospective Study of MRI in Pediatric Patients NCT02291822	Bracco Diagnostics, Inc	—
Terminated	Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients NCT02095353	University of Nebraska	—
Terminated	Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma NCT01582152	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Unknown	Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic NCT01579253	Ludwig-Maximilians - University of Munich	—
Completed	Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment NCT01180881	Massachusetts General Hospital	—
Completed	Coproporphyrine Isomers and Methotrexate Elimination NCT00822432	Assistance Publique - Hôpitaux de Paris	—
Completed	A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patie NCT00329589	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 1
Completed	Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and R NCT00185848	Sanjiv Sam Gambhir	Phase 1
Terminated	Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy NCT00629187	Tufts Medical Center	Phase 1
Completed	EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients NCT00328458	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 1